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ABSTRACT  
An investigation was undertaken of the extent of genetic variation occurring within infectious 
bronchitis virus (IBV) vaccine strains following vaccination of day-old broiler chicks. Chicks 
were divided into seven groups, with two groups receiving single Massachusetts (Mass) 
vaccinations and the other four were inoculated with combinations of different IBV serotypes; 
Mass, 793B, D274, and Arkansas (Ark). The remaining group was maintained as an 
unvaccinated control. Following vaccination, swabs and tissues collected at intervals were 
pooled and RNA was extracted for detection of IBV by reverse transcription polymerase 
chain reaction (RT PCR). Positive amplicons were sequenced for the part-S1 gene and 
compared to the original vaccine strain sequences. Single nucleotide polymorphisms 
(SNPs), amino acid variations and hydrophobicity changes were identified and recorded for 
each sampling point. A total of 106 SNPs were detected within 28 isolates. The average 
SNP counts of swab isolates were greater than those found in tissue samples. This 
translated into 64 amino acid changes, however only six resulted in a change to the 
hydrophobicity properties. All hydrophobic alterations occurred within swab isolates and the 
majority were recovered at 3 days post vaccination suggesting such changes to be 
detrimental to early virus survival. Nucleotide deletions were seen only in the group given the 
combination of Mass and Ark. Of the 16 sequenced samples in this group, 13 contained the 
same AAT deletion at position 1033 1035 in the Ark strains. Findings presented in this study 
demonstrate alteration in the S1 nucleotide sequence following co-administration of live IBV 
vaccines. 
 
Keywords: IBV, live vaccine, PCR and sequencing, SNP, broiler chicks 
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INTRODUCTION 
Infectious bronchitis virus (IBV) is a positive sense single stranded RNA virus and a member 
of the Coronaviridae family (Gonzalez et al., 2003; Cavanagh, 2005). The complete IBV 
genome is around 27.61kb (Cavanagh, 2005) with a GC content of 37.9%. There are a total 
of ten open reading frames (ORFs) that encode ten proteins, four of which are main 
structural proteins. These are the spike (S) glycoprotein, the membrane (M) glycoprotein, the 
nucleocapsid (N) protein and the small envelope (E) protein (Sutou et al., 1988; 
Ammayappan & Vakharia, 2009).  
It has been previously documented that new IBV genotypes can arise as a result of 
genetic alterations (Zhang et al., 2010; Han et al., 2011). This is in part due to the highly 
variable S1 protein, a 1.7kb subunit of the S glycoprotein (Cavanagh et al., 1992). S1 is 
important for attachment of the virus to host cell receptors and induces virus neutralizing and 
haemagglutination inhibition antibodies (Cavanagh et al., 1988; Ignjatovic & Galli, 1994; 
Cavanagh & Gelb, 2008).  
Changes in nucleotide sequences, such as point mutations and insertions or 
deletions (indels), may have a downstream effect on the protein structure and functional 
consequences (Cavanagh, et al., 1992; Studer et al., 2013). However it seems that with S1 
variations, the majority of the remaining virus genome remains unchanged (Cavanagh, et al., 
1992). This has led to suggestions that the currently available vaccines may still offer partial 
protection against challenge from particular variant strains (Cook et al., 1999). Under 
experimental conditions, the extent of genomic variation within the Arkansas (Ark) vaccine 
strain has been previously investigated in SPF chicks (van Santen & Toro, 2008). 
Additionally, the subpopulations present in a number of strains (Mass [M41], Connecticut, 
DE, GA98 and Ark) were examined (McKinley et al., 2008). However, little or no data are 
available for other serotypes of live vaccine viruses such as 793B (eg. 4/91, CR88), D274 
and Mass (e.g. H120 and Ma5).  
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Mass was the first IBV serotype to be identified and subsequent work outlined the poor 
cross-protective nature when compared to other strains at the time, such as the Connecticut 
isolate (de Wit et al., 2011). It is well known that the most widely used live IBV vaccines, for 
example Mass/Mass41/H52/H120/Ma5 are derived from the Massachusetts serotype 
(Bijlenga et al., 2004; Jackwood & de Wit, 2013). There are now a number of recognised live 
Mass vaccine strains (e.g. H52, H120, MM and Ma5). Recent field studies utilising molecular 
approaches have reported the identification of a number of Mass-like variants (Villarreal et 
al., 2010; Han, et al., 2011; Sumi et al., 2012; Fraga et al., 2013). The D274 and Ark 
serotypes were first reported in the 1970s following studies into 15 field strains from the UK 
(Dawson & Gough, 1971) and 40 broiler flocks in Arkansas (Fields, 1973) respectively. Both 
strains are available as commercial vaccines (Gelb & Cloud, 1983; de Wit, et al., 2011). 
Likewise, since its emergence  in the 1990s (Gough et al., 1992), 793B has been reported in 
most poultry producing countries leading to the widespread use of homologous live vaccines 
(e.g. 4/91, CR88, 1/96)  (Jones, 2010). 
Nucleotide variation may affect the antigenic properties of an infecting field strain 
(Cavanagh, et al., 1992), and this could potentially circumvent the protection conferred by 
existing vaccines. Furthermore, should a host be immunosuppressed and have a reduced 
ability to clear an IBV infection, virulent strains can establish within flocks with greater ease 
(Winterfield et al., 1978; Pejkovski et al., 1979). 
In recent years, Sareung et al. (2014) demonstrated the benefit of heterologous live 
vaccination programmes against heterologous IBV challenges (Sarueng et al., 2014). 
Chhabra et al. (2015) and Awad et al. (2016) have reported on concurrent vaccination of 
Mass+793B vaccines and their ability to provide protection against a number of virulent 
variant IBVs. Such simultaneous heterologous IBV vaccination programmes are widely 
practiced, as they are often administered in the hatchery or upon the chick’s arrival at the 
farm. The clinical signs, lesions and immune responses following experimental co-
vaccination have been previously reported (Chhabra et al., 2015; Awad et al., 2016). 
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We report the genomic variations occurring in seven IBV strains from four serotypes 
following simultaneous in vivo inoculation in IBV maternal-antibody positive commercial day-
old chicks (Awad, et al., 2016).  Swabs and tissues collected at intervals from groups of 
chicks that were single or dual vaccinated, were subjected to IBV RT-PCR.  Positive 
samples were sequenced and analysed for single nucleotide polymorphisms (SNPs), amino 
acid changes and hydrophobicity alterations. 
 
MATERIALS AND METHODS 
Chicks and ethical statement. Day-old commercial broiler chicks with maternally-derived 
IBV antibodies (MDA) were obtained from a commercial hatchery. Chicks were kept in an 
isolation unit (University of Liverpool) throughout the experiment and reared on deep litter 
with water and feed provided ad libitum. All experimental procedures were undertaken after 
approval of the University of Liverpool ethical review committee and according to the UK 
legislation on the use of animals for experiments. 
IBV vaccines. Seven commercially available live IBV vaccine viruses were reconstituted in 
sterile distilled water and used either singly or in combination. For this study, the Mass 
vaccines are referred to as Mass1 and Mass2, and the 793B vaccines are referred to as 
793B1 and 793B2. These monovalent vaccines were produced by different manufacturers. 
Mixtures of Mass1+793B1 and of Mass2+793B2 were prepared as previously described 
(Awad, et al., 2016). In addition, commercially combined live vaccines of Mass1+D274 and 
Mass3+Ark were also used (Awad, et al., 2016). Vaccine titres (EID50/chick) were as follows: 
Mass1 (log10 4.0), Mass2 (log10 4.1), 793B1 (log10 4.75), 793B2 (log10 4.4 , Mass1+D274 (log10 
4.3 3) and Mass3+Ark (log10 4.0). All vaccines were prepared prior to administration to 
provide the dosage per chick as recommended by the manufacturers. 
Experimental design. Protocols were as previously described (Awad, et al., 2016). Briefly, 
two hundred and ten day-old chicks were randomly divided into seven groups and kept in 
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separate isolation units, with 30 chicks per group. Each chick was inoculated via the oculo 
(50 µl) and nasal (50 µl) routes with one of the following:  Mass1 (Group 1), Mass2 (Group 2), 
Mass1+D274 (Group 3), Mass1+793B1 (Group 4) Mass2+793B2 (Group 5) Mass3+Ark (Group 
6), and sterile water (Group 7, control). At 3, 6, 10, 14, 18 and 25 days post vaccination 
(dpv), oropharyngeal (OP) and cloacal (CL) swabs, with tissue samples of the trachea (TR), 
duodenum (DU), caecal tonsil (CT) and kidney (KID) were collected from five chicks in each 
group.  
Processing of swab and tissue samples. Both OP and CL swabs from each sampling 
point were pooled.  The swabs were dipped into a sterile tube containing 1.5 ml of Eagles 
serum-free minimum essential medium with glutamine, streptomycin [50 mg/ml] and 
penicillin [50 IU/ml] and stored at -70oC until required.   
Like-tissue samples collected at respective sampling points from the same group 
were pooled and ground up with sterile sand and 1.5 ml of tracheal organ culture medium 
(Minimum Essential Medium, sodium bicarbonate and 0.4% pen/strep) using a pestle and 
mortar. Homogenates were subjected to freeze-thaw three times then centrifuged at 3000 g 
for 15 min (Awad et al., 2014). Supernatants were placed in sterile universal bottles and kept 
at -70oC until required for RT-PCR.  
Detection of IBV by RT-PCR. RNA was extracted from both the swab and tissue samples 
using the phenol chloroform method (Chomczynski & Sacchi, 2006) and subjected to RT-
PCR (Worthington et al., 2008; Ganapathy et al., 2015). In brief, 0.5 μl of extracted RNA was 
used to create cDNA during the reverse-transcriptase (RT) stage with primer SX2− 
(TCCACCTCTAAACACCC/T TT). Created cDNA was then amplified using a nested PCR 
with the following primers SX1+ (CACCTAGAGGTTTGT/CT A/T GCAT), SX2− [PCR 1] and 
SX3+ (TAATACTGGC/T AATTTTTCAGA), SX4− (AATACAGATTGCTTACAACCACC) [PCR 
2]. Reaction products were visualised on a 1.5% agarose gel using electrophoresis. 
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Positive amplicons were purified using 0.15 µl Exonuclease 1 (EXO) and 0.99 µl 
shrimp alkaline phosphatase (SAP) (Affymetrix Ltd, UK) at 37oC for 30 min, then at 80oC for 
10 min to remove extraneous material. Purified products were sent for commercial 
sequencing (Source BioScience, Nottingham, UK) using the positive sense (SX3+) primer 
for analysis of the partial S1 gene. 
All IBV vaccine strains used during the study were extracted, amplified and 
sequenced using the above methodology to allow for comparison of redetected strains to the 
original vaccination strain. Our RT-PCR assay detection limits of the vaccines used in this 
study ranged from log10 1.4 TCID50/ml to log10 2.75 TCID50/ml. 
 
Nucleotide comparison of partial S1 gene sequences within detected vaccine strains. 
Sequence data was initially analysed in ChromasPRO v1.7.3 (http://technelysium.com.au/) 
and BLAST searches were conducted to confirm isolate identification. Alignments were 
carried out in MEGA6 (Tamura et al., 2013), using Clustal W (Thompson et al., 1994). 
Retrieved IBV sequences were identified by comparison against the original vaccine 
sequence and BLAST (National Centre of Biotechnology Information). 
Single nucleotide polymorphism (SNP) and indel detection was carried out in MEGA6 
following alignment to sequenced vaccine strains. SNPs were defined as a nucleotide 
variation when compared to the original vaccine strain which did not alter the sequence 
length. SNPs were characterised as non-synonymous (ns) if they led to an amino acid 
change and synonymous  (if they led to no amino acid changes. Indels were defined as the 
insertion or deletion of a nucleotide that altered the sequence length. The ds/dns ratio was 
calculated for each group using the Nei-Gojobori method (Nei & Kumar, 2000), where <1.0 
indicates the recovered strains to be under positive selective pressure (Fitch et al., 1991). 
Positive selection was considered significant at p<0.05. Translated amino acid variations 
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were also identified and variations that resulted in a change in hydrophobicity were noted 
according to the Kyte and Doolittle scale (Kyte & Doolittle, 1982). 
RESULTS 
RNA from a total of 138 isolates was extracted from tissue samples (n=74) and swabs 
(n=64). Following RT-PCR, interpretable sequence data for the partial S1 gene was obtained 
for 118 (85.51%) of them. Results from BLAST searches confirmed strain identity as the 
same strains as were used for initial vaccination of the birds, with homology ranging from 
89% to 100% (Table 1). IBV strains were recovered from a greater percentage of swab 
samples compared to the tissue samples at each of the sampling points (Figure 1). 
Tissues. The single Mass1 vaccine strain was detected at later stages (10 dpv onwards) and 
persisted in both the caecal tonsil and kidney up to 25 dpv. However, when the combined 
Mass1+793B1 vaccine was given (Group 4), Mass1 was only recovered in the trachea on one 
occasion (10 dpv), whereas the 793B-type strain had distribution within all tissues. For 
Group 3 (Mass1+D274), Mass1 was only detected in the trachea and caecal tonsils from 10 
dpv. The D274-type strain was not detected at any time point.  For the single Mass2 
vaccination, the vaccine strain was detected at 3 dpv in the duodenum and from 10 dpv in 
other tissues. In Group 5, where Mass2 was given in combination with 793B2, it was not 
detected at any time points.  In contrast, the 793B vaccine strain was detected from 3 to 18 
dpv in all sampled tissues, and only in the trachea at 25 dpv. For Group 6 (Mass3+Ark), the 
Mass3 strain was only detected on one occasion at 3 dpv in the trachea, however the Ark-
type strain persisted for longer in the caecal tonsils and kidney (up to 14 dpv) (Table 1). 
Swabs. In the single Mass1 group, the OP swabs were positive from 3 to 18 dpv compared 
to 6-14 dpv for the CL swabs. In the Mass1+793B1 group, Mass1 was only detected up to 10 
dpv in the OP and CL swabs and thereafter only 793B was detected. In the Mass1+D274 
group, only Mass1 was detected in the OP and CL swabs, with D274 not being detected at 
any sampling time.  For the single Mass2 inoculated birds, other than 24 dpv for OP and 3 
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dpv for CL, the strain was consistently detected in both swab locations. In contrast, when 
Mass2 was simultaneously given alongside 793B2, it was only detected at 3 dpv in the OP 
and CL swabs, and at the remaining sampling intervals only 793B2 was detected. In the 
birds where Mass3+Ark was given, the Mass3 strain was only detected at 3 dpv in the OP 
swab and Ark was detected from OP and CL from 10 and 14 dpv respectively (Table 1). 
SNP identification. Following alignment to the relevant vaccine sequence, SNPs were 
identified within the 118 isolates. A total of 28 isolates (tissue = 15 and swabs = 13) 
contained at least one SNP present within their sequence, with the swab isolates having a 
greater number of SNPs overall (83 compared to 23 in the tissue isolates) (Table 2). 
Average SNP counts were higher in the swab isolates with 1.57 per sample compared to 
0.35 per sample in the tissue.  
SNP and amino acid variation analysis. We identified 114 nucleotide variations from the 
36 isolates containing at least one SNP (3.12 per sample). This translated into a total of 64 
amino acid changes (1.78 per sample) from the original vaccine strain. The majority of amino 
acid changes (n=56) occurred in Groups 5 and 6, with the remaining eight in Groups 1 and 2 
(three and five samples respectively). Groups 3 contained only a single SNP and no amino 
acid variations. Group 4 contained no SNPs when compared to the original inoculated strain. 
Virus strains recovered from cloacal and kidney tissue demonstrated a greater 
number of non-synonymous SNPs (7 and 5 respectively) when compared to trachea and 
duodenum tissue isolates (one in both). From the same tissue samples, a greater number of 
SNPs were witnessed after 10 dpv. Interestingly, within Group 6 (Ark-type), all SNPs were 
non-synonymous (n=10) and at the same position (976; thymine to adenine) (Figure 2). This 
resulted in an amino acid change of tyrosine to asparagine; however this did not cause a 
change in hydrophobicity. 
On average, OP swab samples contained a lower total number of SNPs than the CL 
swabs (37 compared to 46). However, OP samples had a ds/dns ratio of 1.42, whereas CL 
10 
 
sequences had a ratio of 0.92. In contrast, the ds/dns ratio for SNPs detected within tissue 
samples was 1.03. Overall, both swab and tissue samples showed no evidence of selective 
pressures (p >0.05). 
Group 6 (Mass3+Ark) was the only group to contain a deletion. Of the 17 sequenced 
samples within the vaccine group (both tissue and swabs), 14 contained the same codon 
deletion (AAT) at position 1033-1035. This deletion removed a single amino acid 
(asparagine), and with no insertions, resulted in an overall smaller S1 protein.  
Two isolates from Group 5 at 3 dpv contained a much higher SNP count of 27 and 30 
(15 and 17 non-synonymous variations respectively). Furthermore, both isolates shared a 
high sequence similarity with each other, with only three nucleotide variations. 
Hydrophobicity changes. Despite there being 64 amino acid changes, only six (9.38%) of 
them resulted in a change of hydrophobicity, at four locations within four isolates (Figure 2). 
All hydrophobicity changes occurred within OP (n=2) and cloacal (n=4) swab samples and 
between amino acid positions 293-334. Of the four locations, two resulted in a switch from 
hydrophilic to hydrophobic whilst the other two were hydrophobic to hydrophilic. Five 
changes occurred in Group 5; the other in Group 2. However, despite the two samples within 
Group 5 being Mass2-like, the changes occurred at different locations when compared to the 
single Mass2 strain (Group 2). 
 
DISCUSSION 
In a previous publication, based on findings from the same experimental birds, we have 
reported on the clinical signs, ciliary health, immune responses and protection against 
virulent IBVs (Awad, et al., 2016).  Due to the increasing use of heterologous vaccination of 
day-old chicks, either in hatcheries or farms, we set out to identify the presence of nucleotide 
variation within the hyper-variable region of S1 in IBV vaccine virus strains following 
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vaccination of day-old commercial broiler chicks. After the live vaccination, samples 
collected at intervals were analysed for the distribution of vaccine viruses in swabs and 
tissues. IBV positive samples were sequenced and analysed for SNPs, and we also 
analysed the downstream effects on the hydrophobic properties of amino acid variations. It 
has previously been suggested that genomic changes within viruses during infection can aid 
with evading the host immune system (Alcami & Koszinowski, 2000), particularly those 
resulting in a change to the antigenic properties of a protein. Further to this, the 
hyper-variable genetic regions of the S1 subunit have previously been well characterised 
(Cavanagh, et al., 1988; Cavanagh et al., 1997). 
In comparison to Awad et al. (2016), additional groups of chickens given a single 
Mass (Mass1 or Mass2) vaccination were included to allow for comparison to those groups 
that received co-vaccination with Mass1+793B1 or Mass2+793B2.  Our results indicate that 
Mass strains can be detected in tissues at an early stage (3 dpv), but only establish 
themselves by 10 dpv when given individually. Redetection can persist to at least 25 dpv. 
However, when given in combination, only the 793B strains were identified at later time 
points (from 14 dpv), suggesting an increased ability for the 793B strains to replicate at a 
greater rate over the Mass strains within the same host. It was interesting to note that both 
793B vaccine strains were detected at all sampling times throughout the experiment, 
demonstrating the persistence of this genotype. Though a single 793B vaccination group 
was not included due to space limitation, previous studies have demonstrated the ability of 
this serotype to persist in broiler chicks until at least 20 days post infection when given alone 
(Boroomand et al., 2012).  In a separate experiment at Liverpool, we recovered 793B 
vaccine strains from the trachea, lungs, caecal tonsil and kidneys of broiler chicks up to the 
end of the experiment (42 days old) (K Ganapathy, unpublished data). 
Strain persistence over time may also increase the likelihood of mutations occurring, 
potentially leading to substantial antigenic alterations over time (McKinley et al., 2011). 
Furthermore, inoculation of multiple IBV serotypes within the same host or system increases 
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the chances of recombination events occurring between the strains (Jia et al., 1995). Despite 
this, we witnessed between 99-100% homology with the original vaccine strain for all 
recovered 793B strains.  This limited variation is in contrast with strains previously identified 
in commercial poultry samples, where greater variations in vaccine strains were witnessed 
(Ganapathy, et al., 2015). The reason for such differences is not known, however previous 
reports have highlighted that the complex interactions between  IBV, host, environment and 
co-infections in the field could have contributed to these differences  (Wickramasinghe et al., 
2011; Sid et al., 2015). 
Strains recovered from swab samples in all groups (n=53) contained an average of 
1.57 SNPs per sample. This was mainly the result of the presence of two Mass-like strains in 
Group 5 (Mass2+793B2) which contained high SNP counts (57 in total). Interestingly, both 
recovered Mass-like strains were from swab samples collected at the same time (3 dpv) and 
shared a high homology (98.91%), despite both only being around 90% similar to the original 
Mass2 vaccine strain. Furthermore, no similar strains were recovered from tissue samples or 
at later time points, suggesting that the changes were limited to a subpopulation present at 
an early stage of vaccination. Such findings agree with previous work which demonstrated 
that when variant subpopulations appear in experimentally infected chickens, it is the original 
infected strain that persists over time, rather than the variations (Toro et al., 2012). 
At no time did we detect the D274 strain in the birds vaccinated with Mass1+D274. 
This could again be explained by a higher replication of the Mass1 strain compared to D274, 
as growth rates have previously been shown to differ between IBV serotypes (Darbyshire et 
al., 1978; Mardani et al., 2008). In addition, viral titres of Mass and D274 within a commercial 
combined vaccine have been shown to differ following co-inoculation of embryonated eggs 
(Geerligs et al., 2013). Alternatively, it may be due to a greater presence and neutralization 
of MDA specific for the D274 strain (Awad, et al., 2016).  Given that D274 was not detected 
by RT-PCR, haemagglutination inhibition testing was carried out on all serum samples, 
including those collected at day 0, to confirm the presence of D274-specific antibodies 
13 
 
following vaccination (data not shown). An antibody response to the D274-specific antigen 
(average titre <2.0 log2) was seen at all times tested.  
All tissue and swab samples from Group 6 (Mass3+Ark) were identified as Ark-like 
(n=16) and had the same SNP change at position 976 (thymine to adenine), altering the 
amino acid from tyrosine to asparagine. With such a variation being common place within 
Ark-type isolates, it would seem to confer a selective advantage to this serotype (Lauring et 
al., 2013). Fourteen of the samples (87.5%) also contained the same three nucleotide 
deletion (AAT) at position 1033-1035. Previous studies have also witnessed the same 
variations within Ark-type vaccine strains from SPF chicks (McKinley, et al., 2008; van 
Santen & Toro, 2008). As the deletion was identified in the caecal tonsil as early as 3 dpv, it 
seems that a subpopulation within the Arkansas vaccine was able to survive and propagate 
following vaccination more readily, when compared to the major population as initially 
detected by Sanger sequencing. While other studies focused on genetic changes in the 
trachea and Harderian gland (McKinley, et al., 2008; van Santen & Toro, 2008), interestingly, 
we discovered that the codon deletion did not occur in Ark-like samples recovered from the 
duodenum. However the reason for this remains unknown. A thorough analysis of Ark-type 
vaccine viruses in oropharyngeal and cloacal swabs, and in various tissues over a longer 
period of time may provide further information for this variable genetic change. 
Interestingly, there were no amino acid variations within recovered strains from either 
Group 3 (Mass1+D274) or 4 (Mass1+793B1). It was only those identified as Mass1-like that 
contained synonymous SNPs. In all twelve strains that were identified as 793B1-like, SNPs 
were entirely absent, suggesting a somewhat stable genome for this 793B1-like strain. 
Previous work by Cavanagh et al., (2005) reported that the majority of SNPs occurring in a 
number of 793B strains were synonymous following passage in embryonated eggs and 
chickens, and did not cause a change in strain pathogenicity (Cavanagh et al., 2005). These 
findings echo the results from this study where the birds were kept under experimental 
conditions.  Conversely, Ganapathy et al. (2015) reported that extensive nucleotide changes 
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were witnessed within the same S1 portion for 793B-like viruses detected within commercial 
chickens. However it is not known if such changes altered pathogenicity (Ganapathy, et al., 
2015). 
Previous work analysed the ds/dns ratios for partial S1 sequences of 793B, Mass and 
D274 (Cavanagh, et al., 2005) and identified that the nucleotide variations were not subject 
to selection pressures. Our experimental vaccination data shows an agreement, as even 
though the overall majority (64/106; 60.38%) of SNPs within recovered IBV strains resulted 
in an amino acid sequence change, the average ds/dns ratio was 1.12. Previous studies have 
indicated that IBV strains isolated from commercial birds may be under selective pressures 
(Mo et al., 2013; Moreno et al., 2016). Positive selection pressure may go some way to 
further our understanding of emerging strain variants. Should the variant strains persist, this 
nucleotide variability also demonstrates the potential for greater hydrophobicity changes in 
the IBV genome over time. 
As the hydrophobic properties of a peptide chain will affect the folding of the 
translated protein structure (Dill, 1990), we investigated hypothetical changes in hydrophobic 
properties arising from nucleotide (and subsequently amino acid) alterations in the partial S1 
sequence. Since the spike glycoprotein is involved with host cell attachment and thought to 
be a causative reasoning behind strain variants (Jackwood et al., 2012), it is possible that 
minor changes could affect the overall function, including the induction of neutralizing and 
haemagluttination inhibiting antibodies. Despite all hydrophobicity changes occurring 
between positions 293-334, those present in the Mass2 samples in Group 5 were at a 
separate location from the change in Mass2 given alone (Group 2). As the only difference 
was the presence of a second strain at the time of inoculation, the additional vaccine strain 
(793B2) may have influenced the mutation rate of the Mass2 virus (Jia, et al., 1995; McKinley, 
et al., 2008). As no Mass2 hydrophobic changes persisted past 14 dpv, it appears that this 
could have provided some advantages for replication and persistence of this virus up to, but 
not beyond, 14 dpv. 
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The Sanger based sequencing approach utilised for this study generates sequence 
data based on the majority population within recovered isolates. As a result minor 
populations of either the same serotype, or different serotypes, would be neglected. During 
analysis minor peaks were only observed for a small number of recovered strains, however 
as the study included combined vaccine groups, a sequencing approach which takes this 
factor into consideration (such as next generation sequencing) may have identified the 
presence of other sub-populations.  
Findings from this first comprehensive study on the effects of live IBV vaccine 
viruses, administered either singly or dually in day-old commercial broiler chicks, 
demonstrated that the majority of SNPs detected within recovered IBV vaccine strains lead 
to amino acid changes. Most such changes occur at an early stage of vaccination (less than 
7 dpv), rather than at later ages. All detected hydrophobic changes occurred solely in OP 
and CL swabs. In IBV-vaccinated commercial broiler chicks with IBV maternal antibodies, it 
appears that the extent of part-S1 amino acid, and resulting hydrophobic changes, were 
limited. 
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Table 1. Genotype identity of recovered IBV strains as determined by BLAST.   206 
Vaccine 
group 
Sample 
froma 
Day post vaccination  
3 6 10 14 18 25 
Group 1 
(Mass1) 
TR - - - Mass1 (99%) Mass1 (99%) - 
DU - - - Mass1 (99%) - - 
CT - - Mass1 (99%) Mass1 (99%) Mass1 (99%) Mass1 (98%) 
KID - - - - - - 
OP Mass1 (100%) Mass1 (100%) Mass1 (100%) Mass1 (100%) Mass1 (99%) - 
CL - Mass1 (99%) Mass1 (100%) Mass1 (100%) - - 
Group 2 
(Mass2) 
TR - - Mass2 (99%) - - - 
DU Mass2 (99%) - Mass2 (99%) - - - 
CT - - Mass2 (99%) Mass2 (99%) Mass2 (99%) Mass2 (99%) 
KID - - - Mass2 (99%) - Mass2 (99%) 
OP Mass2 (100%) Mass2 (100%) Mass2 (100%) Mass2 (100%) Mass2 (100%) - 
CL - Mass2 (100%) Mass2 (100%) Mass2 (98%) Mass2 (100%) Mass2 (99%) 
Group 3 
(Mass1+D274) 
TR - - Mass1 (99%) Mass1 (100%) Mass1 (99%) - 
DU - - - - - - 
CT - - - Mass1 (99%) - Mass1 (99%) 
KID - - - - - - 
OP Mass1 (100%) Mass1 (100%) Mass1 (100%) Mass1 (100%) Mass1 (100%) - 
CL - Mass1 (100%) Mass1 (100%) - Mass1 (100%) - 
Group 4 
(Mass1+793B1) 
TR - - Mass1 (99%) - 793B1 (100%) 793B1 (100%) 
DU - 793B1 (100%) - 793B1 (99%) 793B1 (100%) - 
CT - 793B1 (100%) 793B1 (100%) 793B1 (100%) 793B1 (100%) 793B1 (100%) 
KID - - 793B1 (99%) - - - 
OP Mass1 (100%) Mass1 (100%) Mass1 (100%) 793B1 (100%) 793B1 (100%) 793B1 (100%) 
CL Mass1 (100%) 793B1 (100%) - 793B1 (100%) 793B1 (100%) 793B1 (100%) 
Group 5 
(Mass2+793B2) 
TR 793B2 (100%) 793B2 (100%) 793B2 (100%) 793B2 (100%) - 793B2 (100%) 
DU 793B2 (100%) 793B2 (100%) 793B2 (100%) 793B2 (100%) 793B2 (100%) - 
CT 793B2 (100%) 793B2 (100%) 793B2 (100%) 793B2 (100%) 793B2 (100%) - 
KID 793B2 (100%) 793B2 (100%) 793B2 (100%) 793B2 (100%) 793B2 (100%) - 
OP Mass2 (90%) - - 793B2 (100%) - 793B2 (100%) 
CL Mass2 (89%) 793B2 (100%) 793B2 (99%) 793B2 (100%) 793B2 (100%) 793B2 (100%) 
Group 6 
(Mass3+Ark) 
TR Mass3 (100%) - Ark (100%) - - - 
DU - - Ark (99%) - - - 
CT Ark (99%) - Ark (100%) Ark (99%) - - 
KID - Ark (99%) Ark (99%) Ark (99%) - - 
OP Mass3 (100%) - Ark (99%) Ark (99%) Ark (99%) Ark (99%) 
CL - -   Ark (99%) Ark (97%) Ark (95%) 
 207 
Brackets indicate homology to vaccine strain. 208 
 aTR -Trachea;  209 
DU -Duodenum  210 
22 
 
CT -Caecal tonsil  211 
KID - Kidney 212 
OP - Oropharyngeal swab  213 
CL - Cloacal swab 214 
 215 
216 
23 
 
Table 2. Summary of SNP data from recovered isolates, including non-synonymous SNPs and 217 
relevant hydrophobicity changes.  218 
 219 
  Total 
Sample 
Number 
Samples 
Containing 
≥1 SNP 
Number of SNPs 
Deletions 
Total 
Amino 
Acid 
Changes 
Hydrophobicity 
Changes   Synonymous Non-synonymous 
      
A 
Location TRa 15 3 4 1 3 2 0 
DUb 13 2 1 1 0 1 0 
CTc 23 5 1 7 12 11 0 
KIDd 14 5 3 5 12 9 0 
Days post 
vaccination 
3 6 1 0 1 3 2 0 
6 7 1 0 1 3 2 0 
10 16 5 1 4 9 7 0 
14 16 4 4 3 6 5 0 
18 11 3 3 2 6 4 0 
  25 9 1 1 3 0 3 0 
Vaccine group 
Mass1 7 2 2 3 0 3 0 
Mass2 9 1 3 1 0 1 0 
Mass1+D274 5+0 1+0 3+0 0+0 0+0 0+0 0+0 
Mass1+793B1 1+12 1+0 1+0 0+0 0+0 0+0 0+0 
Mass2+793B2 0+21 0+0 0+0 0+0 0+0 0+0 0+0 
  Mass3+Ark 0+10 0+10 0+0 0+10 0+27 0+19 0+0 
B 
Location OPe 29 7 14 23 12 22 2 
  CLf 24 6 19 27 3 21 4 
Days post 
vaccination 
3 8 3 27 35 0 24 4 
6 9 1 2 0 0 0 0 
10 9 2 1 2 3 3 1 
14 11 4 1 7 6 9 1 
18 10 2 2 5 3 5 0 
25 6 1 0 1 3 2 0 
Vaccine group 
Mass1 8 1 2 0 0 0 0 
Mass2 10 1 1 4 0 4 1 
Mass1+D274 8+0 0+0 0+0 0+0 0+0 0+0 0+0 
Mass1+793B1 4+7 0+0 0+0 0+0 0+0 0+0 0+0 
Mass2+793B2 2+7 2+2 25+1 32+2 0+0 24+3 4 +1 
  Mass3+Ark 1+6 1+6 1+3 3+9 0+15 3+9 0+0 
A Tissue samples  220 
B Swab samples  221 
aTR -Trachea 222 
bDU - Duodenum 223 
cCT - Caecal tonsil 224 
24 
 
dKID - Kidney 225 
eOP - Oropharyngeal swab  226 
fCL - Cloacal swab 227 
 228 
FIGURE LEGENDS 229 
Figure 1. IBV strain recovery rates given as a percentage for both swab (14 per time point) 230 
and tissue (28 per time point) samples up to 25 days post vaccination. 231 
 232 
 233 
Figure 2. Hydrophobicity changes occurring within each vaccinated group. Each sample is 234 
identified by swab location, either oropharyngeal of cloacal and days post vaccination. 235 
Amino acids coloured red are hydrophobic and blue are hydrophilic. Asterisks indicate the 236 
position of a change in hydrophobicity. A: Mass2-type strain used for vaccination, B: 237 
Mass2+793B2 vaccine group (Mass2-type samples) and C: Mass2+793B2 vaccine group 238 
(793B2-type samples). 239 
 240 
25 
 
 241 
26 
 
 242 
